肠道微生物群短链脂肪酸作为改善糖尿病的关键病理生理分子的证据。
Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes.
作者信息
Puddu Alessandra, Sanguineti Roberta, Montecucco Fabrizio, Viviani Giorgio Luciano
机构信息
First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, IRCCS Azienda Ospedaliera Universitaria San Martino, 6 Viale Benedetto XV, 16143 Genoa, Italy.
First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, IRCCS Azienda Ospedaliera Universitaria San Martino, 6 Viale Benedetto XV, 16143 Genoa, Italy ; Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, Geneva University Hospitals, 64 Avenue de la Roseraie, 1211 Geneva, Switzerland ; Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland.
出版信息
Mediators Inflamm. 2014;2014:162021. doi: 10.1155/2014/162021. Epub 2014 Aug 17.
In type 2 diabetes, hyperglycemia, insulin resistance, increased inflammation, and oxidative stress were shown to be associated with the progressive deterioration of beta-cell function and mass. Short-chain fatty acids (SCFAs) are organic fatty acids produced in the distal gut by bacterial fermentation of macrofibrous material that might improve type 2 diabetes features. Their main beneficial activities were identified in the decrease of serum levels of glucose, insulin resistance as well as inflammation, and increase in protective Glucagon-like peptide-1 (GLP-1) secretion. In this review, we updated evidence on the effects of SCFAs potentially improving metabolic control in type 2 diabetes.
在2型糖尿病中，高血糖、胰岛素抵抗、炎症增加和氧化应激与β细胞功能和质量的逐渐恶化有关。短链脂肪酸（SCFAs）是由肠道远端的细菌对大纤维物质进行发酵产生的有机脂肪酸，可能改善2型糖尿病的特征。它们的主要有益作用体现在降低血清葡萄糖水平、胰岛素抵抗以及炎症，并增加具有保护作用的胰高血糖素样肽-１（GLP-1）的分泌。在本综述中，我们更新了关于短链脂肪酸可能改善2型糖尿病代谢控制作用的证据。
Zotero 插件